Anti-CML monoclonal antibody, clone EOS-22

In this study the authors propose a novel and straightforward design procedure for the single-ended ring oscillator (SERO). This procedure determines the values of the circuit parameters to reach the desired oscillation frequency while the power consumption and the area are minimised and the noise is kept below the desired value. Furthermore, the authors analyse the SERO and suggest a practical formula for the oscillation frequency. In comparison to the conventional equations, the derived formula is accurate as well as explicit. The accuracy of the proposed frequency equation is verified using simulation. The average of the absolute errors over a wide range of parameters is 2.52%, and the worst case error is 9.64%. In addition, the power consumption of the SERO is analysed and a formula is presented for estimating the power consumption.

Treatment-free remission (TFR) is emerging as a new therapy goal for chronic myeloid leukemia (CML) patients in the tyrosine kinase inhibitors (TKI) era. Data indicates the unfavorable success rate of TFR. This study aimed to compare and evaluate the clinical value of dd-PCR in predicting relapse in CML patients entering TFR. Using dd-PCR and RT-qPCR technology, dynamic BCR/ABL transcripts were detected in 13 CML patients who discontinued TKI treatment after sustaining undetectable BCR-ABL levels for a median time of 25 months. The results showed that in 13 patients, only 2 cases (22.2%) of 9 patients who executed planned discontinuation achieved TFR within 12 months. In the first 6 months, the detection rate of BCR/ABL transcripts by dd-PCR was higher than that by RT-qPCR and the two methods kept a positive correlation (r=0.9651, P=0.0349). Meanwhile, the time of detectable BCR/ABL by dd-PCR were significantly shorter (P<0.05), which was an average of 2.98 months earlier than RT-qPCR. The total TKI therapy and MR4.5 duration time related with TFR were longer in patients with intermediate or high Sokal risk scores (p<0.05). The dd-PCR could be more sensitive than RT-qPCR for monitoring BCR/ABL transcripts of CML patients with deep molecular response to TKI. The technique can be used as a preferred method to detect the transcripts in the first 6 months after TKI cessation.